ImmuCell Corporation (ICCC)
| Market Cap | 91.55M +96.1% |
| Revenue (ttm) | 29.93M +9.6% |
| Net Income | -545,403 |
| EPS | -0.07 |
| Shares Out | 9.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,470 |
| Open | 10.01 |
| Previous Close | 10.01 |
| Day's Range | 9.71 - 10.20 |
| 52-Week Range | 4.52 - 10.25 |
| Beta | 0.50 |
| Analysts | Strong Buy |
| Price Target | 14.00 (+37.8%) |
| Earnings Date | May 14, 2026 |
About ICCC
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mast... [Read more]
Financial Performance
In 2025, ImmuCell's revenue was $27.64 million, an increase of 4.34% compared to the previous year's $26.49 million. Losses were -$1.04 million, -51.78% less than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for ICCC stock is "Strong Buy" and the 12-month stock price target is $14.0.
News
ImmuCell Q1 Earnings Call Highlights
ImmuCell NASDAQ: ICCC reported a record first quarter of 2026, with management saying the company's narrowed focus on its First Defense calf scours prevention portfolio helped drive its first-ever qua...
ImmuCell Earnings Call Transcript: Q1 2026
Record Q1 2026 revenue and net income growth driven by strong Tri-Shield sales, margin expansion, and increased U.S. market share. Capacity and sales force investments support continued growth, with international expansion and plant upgrades underway.
ImmuCell Quarterly report: Q1 2026
ImmuCell has published its Q1 2026 quarterly earnings report on May 15, 2026.
ImmuCell Earnings release: Q1 2026
ImmuCell released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
ImmuCell Slides: Q1 2026
ImmuCell has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 15, 2026.
ImmuCell Slides: Investor presentation
ImmuCell has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
PORTLAND, Maine, May 14, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve ca...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026
PORTLAND, Maine, May 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve ca...
ImmuCell Proxy statement: Proxy filing
ImmuCell filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
ImmuCell Proxy statement: Proxy filing
ImmuCell filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors
PORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve ...
ImmuCell Slides: Investor presentation
ImmuCell has posted slides in relation to its latest quarterly earnings report, which was published on April 13, 2026.
ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
PORTLAND, Maine, April 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets produc...
ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board
PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets produc...
ImmuCell Earnings Call Transcript: Q4 2025
2025 saw 4.3% sales growth to $27.6M, gross margin rise to 41%, and a $3.3M operating income swing, driven by expanded capacity and a strategic focus on First Defense. Net loss narrowed to $1M despite significant non-cash write-downs.
ImmuCell Annual report: Q4 2025
ImmuCell has published its Q4 2025 annual report on March 5, 2026.
ImmuCell Earnings release: Q4 2025
ImmuCell released its Q4 2025 earnings on March 5, 2026, summarizing the period's financial results.
ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025
PORTLAND, Maine, March 04, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that im...
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025
PORTLAND, Maine, Feb. 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that imp...
ImmuCell Earnings Call Transcript: Q4 2025
Strategic focus shifted to First Defense after FDA setbacks for Re-Tain, driving strong domestic sales and operational improvements. Q4 2025 sales reached $7.6M, with Tri-Shield up 41.3% year-over-year, while international sales declined. Asset repurposing and team expansion support future growth.
ImmuCell Earnings release: Q4 2025
ImmuCell released its Q4 2025 earnings on January 9, 2026, summarizing the period's financial results.
Immucell reports preliminary Q4 revenue $7.6M
Reports preliminary FY25 revenue $27.6M. “Sales for the quarter exceeded our expectations and show that we continue to make progress rebuilding our market position after a period of supply challenges,...
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025
PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that imp...
ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus
PORTLAND, Maine, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that imp...
Immucell to pause further investment in Re-Tain after FDA Incomplete Letter
ImmuCell (ICCC) Corporation announced that it received an Incomplete Letter from the FDA on December 23 for its Re-Tain New Animal Drug Application, or NADA, and simultaneously that it is…